Test Price
2,800 AED✅ Home Collection Available
UGT1A1 Gene Gilbert Syndrome Genetic Test in UAE – 2800 AED – DHA Licensed
Executive Summary & Core Metrics
-
✔
Diagnostic Accuracy: >99.9% sensitivity for UGT1A1 promoter and coding region variants via ISO 9001:2015 accredited Next-Generation Sequencing.
-
✔
Turnaround Time: 3–4 weeks including confirmatory Sanger validation and genetic counseling report.
-
✔
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection daily from 8 AM to 11 PM.
-
✔
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
-
✔
Genetic Counseling: Pre- and post-test telephonic counselling included by DHA-licensed genetics professionals.
💰 Price
2,800 AED
Inclusive of GST, genomic reporting, and genetic counselling
Test Overview & Methodology
This Next-Generation Sequencing assay analyses the full UGT1A1 gene including the promoter TATA box, all five exons, and flanking intronic regions to detect single nucleotide variants and small insertions/deletions associated with Gilbert syndrome. The test provides definitive molecular confirmation of benign unconjugated hyperbilirubinemia, eliminating the need for repeated invasive liver investigations.
| Feature | DNA Labs UAE NGS Panel | Alternative PCR-Based Methods |
|---|---|---|
| Gene Coverage | Full UGT1A1 (promoter, exons, intronic boundaries, CNV detection) | Limited to TA-repeat region (>70% of variants) |
| Variant Types Detected | SNVs, indels, promoter variants, copy number changes | Only TA-repeat expansions |
| False Negative Rate | <0.1% (Sanger confirmation of all clinically relevant calls) | 20–30% (misses rare and non-TA variants) |
| Genetic Counselling | Pre- and post-test with board-certified genetic counsellor | Not included |
| Regulatory Certification | DHA licensed, ISO 9001:2015, UAE PDPL compliant | May lack UAE laboratory accreditation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“A molecularly confirmed diagnosis of Gilbert syndrome provides reassurance that the unconjugated hyperbilirubinemia is benign and does not require treatment. The UGT1A1 NGS panel is the gold standard for definitive diagnosis and avoids unnecessary and costly hepatobiliary investigations. Results must always be interpreted alongside total and fractionated bilirubin levels and liver enzyme profiles by the referring clinician.”
Clinical Advisory – Medication & Management
Gilbert syndrome does not require pharmacological intervention. Patients should be informed that the condition is benign and has no impact on life expectancy. However, certain medications metabolised via UDP-glucuronosyltransferase (e.g., irinotecan, atazanavir) may require dose adjustment. Do not discontinue or alter prescribed medications without consulting your treating physician. A detailed pharmacogenomic report is appended to the molecular result.
Exclusion Criteria & Emergency Red Flags
- Not for acute care: This elective test is not a substitute for urgent evaluation of acute jaundice or hepatocellular injury.
- Exclusion: Patients with decompensated chronic liver disease, acute viral hepatitis, biliary obstruction, or known hepatocellular carcinoma should not delay emergency medical assessment.
- Emergency signs: Seek immediate emergency care if you develop severe jaundice, dark urine, pale stools, right upper quadrant pain, confusion, or new-onset ascites.
- Contraindication: This test is not validated for neonatal or paediatric populations outside the approved clinical indication.
Patient FAQ & Clinical Guidance
1. What is the UGT1A1 gene test and why would I need it for mild jaundice?
This NGS test confirms or excludes Gilbert syndrome, the most common cause of benign unconjugated hyperbilirubinemia. A definitive molecular diagnosis prevents repeated blood work, liver imaging, and unnecessary specialist referrals, reducing healthcare costs and patient anxiety.
2. Can I provide a blood spot card instead of a venous blood draw?
Yes. DNA extracted from a single dried blood spot on an FTA card yields equivalent NGS quality to venous whole blood when processed under ISO 9001:2015 controlled protocols. A trained phlebotomist can collect the finger-prick sample during a home visit.
3. Does the test cover all known UGT1A1 mutations and what does a negative result mean?
The panel detects all clinically significant promoter (including the common TA7 allele), coding, and splice-site variants. A negative result excludes Gilbert syndrome with >99.9% confidence and should prompt further hepatology evaluation to identify alternative causes of unconjugated hyperbilirubinemia such as Crigler-Najjar or hemolytic disorders.
4. How long does it take to get results and how are they delivered?
Turnaround time is 3–4 weeks from sample receipt. Results are delivered via secure digital portal with a comprehensive molecular report that includes variant classification, clinical correlation, and a pharmacogenomic appendix. A follow-up telephonic counselling session is scheduled within 48 hours of report release.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – All genetic data is processed, stored, and transmitted in full compliance with UAE federal privacy regulations.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Digital health records and tele-counselling platforms adhere to this statute for secure electronic health information exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – Clinical testing, patient consent, and safety protocols conform to this law governing medical professional responsibility and patient rights.
🔒 DHA Licensed Facility
License No. 1143
Premises 105, Floor 1, Building 33
Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | UGT1A1 Gene Gilbert Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED (incl. GST, genomic report, and genetic counselling) |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or FTA blood spot card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full UGT1A1 gene including promoter, exons, and CNV analysis |
| ICD-10-CM Code | E80.4, Z14.8, Z13.79 |
| LOINC Code | 77745-3 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians